WO2005030215A3 - Therapeutic treatment - Google Patents

Therapeutic treatment Download PDF

Info

Publication number
WO2005030215A3
WO2005030215A3 PCT/GB2004/004120 GB2004004120W WO2005030215A3 WO 2005030215 A3 WO2005030215 A3 WO 2005030215A3 GB 2004004120 W GB2004004120 W GB 2004004120W WO 2005030215 A3 WO2005030215 A3 WO 2005030215A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic treatment
prevention
treatment
candesartan
rosuvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/004120
Other languages
French (fr)
Other versions
WO2005030215A2 (en
Inventor
Jay Lal Mehta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP04768663A priority Critical patent/EP1673091B1/en
Priority to AU2004275567A priority patent/AU2004275567B2/en
Priority to CA2540102A priority patent/CA2540102C/en
Priority to JP2006527488A priority patent/JP4841433B2/en
Priority to NZ546162A priority patent/NZ546162A/en
Priority to HK06111293.5A priority patent/HK1090553B/en
Priority to DE602004024555T priority patent/DE602004024555D1/en
Priority to MXPA06003353A priority patent/MXPA06003353A/en
Priority to HR20100080T priority patent/HRP20100080T1/en
Priority to DK04768663.9T priority patent/DK1673091T3/en
Priority to UAA200603434A priority patent/UA90249C2/en
Priority to PL04768663T priority patent/PL1673091T3/en
Priority to AT04768663T priority patent/ATE451103T1/en
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to BRPI0414724-3A priority patent/BRPI0414724A/en
Priority to SI200431337T priority patent/SI1673091T1/en
Priority to US10/573,353 priority patent/US7932263B2/en
Priority to KR1020067007973A priority patent/KR101129767B1/en
Publication of WO2005030215A2 publication Critical patent/WO2005030215A2/en
Publication of WO2005030215A3 publication Critical patent/WO2005030215A3/en
Priority to IL174536A priority patent/IL174536A/en
Anticipated expiration legal-status Critical
Priority to NO20061744A priority patent/NO335813B1/en
Priority to IS8421A priority patent/IS2729B/en
Priority to US12/813,917 priority patent/US20110046119A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A combination comprising candesartan and rosuvastatin for the prevention or treatment of arteriosclerosis and for the prevention of cardiovascular events is described.
PCT/GB2004/004120 2003-09-26 2004-09-22 Therapeutic treatment Ceased WO2005030215A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
AT04768663T ATE451103T1 (en) 2003-09-26 2004-09-22 COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS CONTAINING CANDESARTAN AND ROSUVASTATIN
CA2540102A CA2540102C (en) 2003-09-26 2004-09-22 A combination of candesartan and rosuvastatin for the treatment of atherosclerosis
JP2006527488A JP4841433B2 (en) 2003-09-26 2004-09-22 Therapeutic treatment
NZ546162A NZ546162A (en) 2003-09-26 2004-09-22 Therapeutic treatment
HK06111293.5A HK1090553B (en) 2003-09-26 2004-09-22 A combination comprising candesartan and rosuvastatin for the treatment of atherosclerosis
DE602004024555T DE602004024555D1 (en) 2003-09-26 2004-09-22 A composition for the treatment of atherosclerosis containing candesartan and rosuvastatin
MXPA06003353A MXPA06003353A (en) 2003-09-26 2004-09-22 Therapeutic treatment.
HR20100080T HRP20100080T1 (en) 2003-09-26 2004-09-22 A combination comprising candesartan and rosuvastatin for the treatment of atherosclerosis
AU2004275567A AU2004275567B2 (en) 2003-09-26 2004-09-22 Therapeutic treatment
UAA200603434A UA90249C2 (en) 2003-09-26 2004-09-22 Combination comprising candesartan and rosuvastatin, pharmaceutical composition comprising thereof and use
PL04768663T PL1673091T3 (en) 2003-09-26 2004-09-22 A combination comprising candesartan and rosuvastatin for the treatment of atherosclerosis
EP04768663A EP1673091B1 (en) 2003-09-26 2004-09-22 A combination comprising candesartan and rosuvastatin for the treatment of atherosclerosis
BRPI0414724-3A BRPI0414724A (en) 2003-09-26 2004-09-22 combination, pharmaceutical composition, methods for preventing or treating atherosclerosis in a warm-blooded animal and for preventing cardiovascular events in a warm-blooded animal;
DK04768663.9T DK1673091T3 (en) 2003-09-26 2004-09-22 Composition containing candesartan and rosuvastatin for the treatment of atherosclerosis
SI200431337T SI1673091T1 (en) 2003-09-26 2004-09-22 A combination comprising candesartan and rosuvastatin for the treatment of atherosclerosis
US10/573,353 US7932263B2 (en) 2003-09-26 2004-09-22 Therapeutic treatment
KR1020067007973A KR101129767B1 (en) 2003-09-26 2004-09-22 Therapeutic treatment
IL174536A IL174536A (en) 2003-09-26 2006-03-23 Combination comprising candesartan and rosuvastatin, pharmaceutical compositions comprising such combination and use of such combination as a medicament for the prevention or treatment of atherosclerosis or cardiovascular events
NO20061744A NO335813B1 (en) 2003-09-26 2006-04-20 Combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof for the prevention or treatment of disease
IS8421A IS2729B (en) 2003-09-26 2006-04-21 A composition comprising candesartan and rosuvastatin for the treatment of nodal sclerosis
US12/813,917 US20110046119A1 (en) 2003-09-26 2010-06-11 Therapeutic treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322552.1A GB0322552D0 (en) 2003-09-26 2003-09-26 Therapeutic treatment
GB0322552.1 2003-09-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/813,917 Continuation US20110046119A1 (en) 2003-09-26 2010-06-11 Therapeutic treatment

Publications (2)

Publication Number Publication Date
WO2005030215A2 WO2005030215A2 (en) 2005-04-07
WO2005030215A3 true WO2005030215A3 (en) 2005-06-02

Family

ID=29286881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004120 Ceased WO2005030215A2 (en) 2003-09-26 2004-09-22 Therapeutic treatment

Country Status (28)

Country Link
US (2) US7932263B2 (en)
EP (1) EP1673091B1 (en)
JP (1) JP4841433B2 (en)
KR (1) KR101129767B1 (en)
CN (1) CN100515421C (en)
AT (1) ATE451103T1 (en)
AU (1) AU2004275567B2 (en)
BR (1) BRPI0414724A (en)
CA (1) CA2540102C (en)
CY (1) CY1109814T1 (en)
DE (1) DE602004024555D1 (en)
DK (1) DK1673091T3 (en)
ES (1) ES2336450T3 (en)
GB (1) GB0322552D0 (en)
HR (1) HRP20100080T1 (en)
IL (1) IL174536A (en)
IS (1) IS2729B (en)
MX (1) MXPA06003353A (en)
NO (1) NO335813B1 (en)
NZ (1) NZ546162A (en)
PL (1) PL1673091T3 (en)
PT (1) PT1673091E (en)
RU (1) RU2358737C2 (en)
SG (1) SG145773A1 (en)
SI (1) SI1673091T1 (en)
UA (1) UA90249C2 (en)
WO (1) WO2005030215A2 (en)
ZA (1) ZA200602433B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
BR112012006939A2 (en) * 2009-09-29 2015-09-08 Butamax Tm Advanced Biofuels Recombinant yeast production host cell and method for producing a product selected from the group consisting of 2,3-butanediol, isobutanol, 2-butanol, 1-butanol, 2-butanone, valine, leucine, lactic acid, malic acid , alcohol, isoampyl and isoprenoids
US20120239131A1 (en) * 2011-03-15 2012-09-20 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysmal tissue
WO2013083286A1 (en) * 2011-12-09 2013-06-13 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
CN103479627A (en) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 Application of I-type acceptor antagonist of angiotensin II to promote hair growth
KR101771766B1 (en) 2013-12-30 2017-08-28 알보젠코리아 주식회사 Pharmaceutical combination comprising Angiotensin-Ⅱ Receptor Blocker and HMG-CoA Reductase Inhibitor
UA122847C2 (en) * 2016-11-15 2021-01-06 Елджі Кем, Лтд. TREATMENT COMPLEX FOR THE TREATMENT OF TYPE TWO DIABETES AND DIABETIC DYSLIPIDEMIA

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
JP2002145770A (en) * 2000-08-30 2002-05-22 Sankyo Co Ltd Pharmaceutical composition for prophylaxis or treatment of cardiac insufficiency
EP1314425A1 (en) * 2000-08-30 2003-05-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
WO2004096810A1 (en) * 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
FR2741620B1 (en) 1995-11-28 1997-12-26 Oreal PROCESS FOR THE PREPARATION OF COMPOUNDS WITH A BETA-HYDROXY -DELTA-LACTONE GROUP ANALOGS OF (+) COMPACTIN AND (+) MEVINOLINE
PL189066B1 (en) 1996-04-05 2005-06-30 Takeda Pharmaceutical Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
DE69734405T2 (en) * 1996-07-15 2006-08-03 Sankyo Co., Ltd. Use of CS-866 (Olmersartan) for the manufacture of a medicament for the treatment of arteriosclerosis
JPH1081633A (en) 1996-07-16 1998-03-31 Sankyo Co Ltd Medicinal composition
GT199800126A (en) 1997-08-29 2000-01-29 COMBINATION THERAPY.
HN1998000124A (en) 1997-08-29 1999-02-09 Pfizer Prod Inc COMBINATION THERAPY
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
AR022462A1 (en) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd USE OF AN AGENT THAT DECREASES CHOLESTEROL
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TR200102944T2 (en) 1999-04-13 2002-08-21 Basf Aktiengesellschaft Integrin receptor ligands
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AR030414A1 (en) 2000-04-03 2003-08-20 Astrazeneca Ab PHARMACEUTICAL COMBINATION THAT INCLUDES A BLOCKING BETA AND A REDUCED HMG-COA INHIBITOR, PHARMACEUTICAL FORMULATION, TRANSPORTABLE PARTS EQUIPMENT, USE OF THIS COMBINATION AND THIS FORMULATION TO PREPARE MEDICATIONS
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
RU2298418C2 (en) * 2000-04-12 2007-05-10 Новартис Аг Combination of at least two compounds chosen from groups at1-receptor antagonists or inhibitors of ace (angiotensin-converting enzyme) or inhibitors of hmg-coa-reductase (beta-hydroxy-beta-methylglutaryl-coenzyme-a-reductase)
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
PT1385548E (en) * 2001-01-26 2007-08-24 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
AR035533A1 (en) * 2001-01-26 2004-06-02 Schering Corp USE OF AT LEAST AN INHIBITOR OF THE ABSORPTION OF THE STEROLS OR THEIR SALTS, SOLVATOS, PHARMACEUTICALLY ACCEPTABLE DRUGS OR MIXTURES OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF SITOSTEROLEMIA, COMPOSITIONS OF THE PHARMACEUTICAL USE
WO2002095402A2 (en) * 2001-04-18 2002-11-28 Mcgill University Individualization of therapy with hyperlipidemia agents
SE0103509D0 (en) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre-demented states
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2005126338A (en) 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Heart failure treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
JP2002145770A (en) * 2000-08-30 2002-05-22 Sankyo Co Ltd Pharmaceutical composition for prophylaxis or treatment of cardiac insufficiency
EP1314425A1 (en) * 2000-08-30 2003-05-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
WO2004096810A1 (en) * 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN JIAWEI ET AL: "Marked upregulation of lipoxygenase-1, a receptor for ox-low-density lipoprotein in atherosclerosis, and its total ablation by candesartan and rosuvastatin given concurrently.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 43, no. 5 Supplement A, 3 March 2004 (2004-03-03), & 53RD ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY; NEW ORLEANS, LA, USA; MARCH 07-10, 2004, pages 498A, XP002319611, ISSN: 0735-1097 *
PATENT ABSTRACTS OF JAPAN vol. 2002, no. 09 4 September 2002 (2002-09-04) *

Also Published As

Publication number Publication date
AU2004275567B2 (en) 2008-01-10
IS8421A (en) 2006-04-21
DE602004024555D1 (en) 2010-01-21
DK1673091T3 (en) 2010-03-22
HK1090553A1 (en) 2006-12-29
JP4841433B2 (en) 2011-12-21
IL174536A (en) 2010-12-30
US7932263B2 (en) 2011-04-26
PT1673091E (en) 2010-02-15
AU2004275567A1 (en) 2005-04-07
ZA200602433B (en) 2007-06-27
NO20061744L (en) 2006-06-22
IS2729B (en) 2011-04-15
SG145773A1 (en) 2008-09-29
US20110046119A1 (en) 2011-02-24
IL174536A0 (en) 2008-04-13
CA2540102A1 (en) 2005-04-07
RU2358737C2 (en) 2009-06-20
ES2336450T3 (en) 2010-04-13
CY1109814T1 (en) 2014-09-10
EP1673091B1 (en) 2009-12-09
RU2006113366A (en) 2007-11-10
KR101129767B1 (en) 2012-03-26
EP1673091A2 (en) 2006-06-28
MXPA06003353A (en) 2006-06-08
BRPI0414724A (en) 2006-11-21
SI1673091T1 (en) 2010-03-31
ATE451103T1 (en) 2009-12-15
CN100515421C (en) 2009-07-22
CA2540102C (en) 2012-07-24
JP2007506720A (en) 2007-03-22
NO335813B1 (en) 2015-02-23
UA90249C2 (en) 2010-04-26
PL1673091T3 (en) 2010-04-30
CN1886136A (en) 2006-12-27
GB0322552D0 (en) 2003-10-29
WO2005030215A2 (en) 2005-04-07
KR20060108623A (en) 2006-10-18
HRP20100080T1 (en) 2010-04-30
NZ546162A (en) 2008-11-28
US20070275989A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
CY1109814T1 (en) A combination containing CANDESARTAN and ROSUVASTATIN for therapeutic treatment of arteriosclerosis
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
PL377344A1 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
SI1487541T1 (en) Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
PL374846A1 (en) New compounds for the inhibition of rotamases and use thereof
AU2003229923A1 (en) Curcumin for the prevention and/or treatment of tissue damage
AU2003291480A1 (en) Composition for the prevention and treatment of inflammation of the ear
WO2001085201A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
AU2003237739A1 (en) Combination of a reflux inhibitor and an imidazopyridine for the treatment of gerd
MXPA03006776A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003231279A1 (en) Prevention and treatment of type 2 diabetes
WO2002096516A8 (en) Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
AU2003239494A1 (en) Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
AU2003239284A1 (en) Combination of pde-v inhibitors and nk1 antagonists for the treatment of depression
PL373000A1 (en) Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
AU2003304316A1 (en) Compounds and methods for the treatment and prevention of bacterial infection
AU2003208288A1 (en) Deuterated biphenyl-substituted benzimidazoles and medicament containing said compounds for the treatment of hypertonia
AU2003227257A1 (en) Medicine for prevention and/or therapy of cardiomyopathy
AU2002315372A1 (en) Combination of a ppar-alpha ligand and glucocorticoid for the treatment or prevention of inflammation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480034823.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004275567

Country of ref document: AU

Ref document number: 174536

Country of ref document: IL

Ref document number: 2540102

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006/02433

Country of ref document: ZA

Ref document number: 546162

Country of ref document: NZ

Ref document number: PA/a/2006/003353

Country of ref document: MX

Ref document number: 12006500608

Country of ref document: PH

Ref document number: 200602433

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006527488

Country of ref document: JP

Ref document number: 1649/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004275567

Country of ref document: AU

Date of ref document: 20040922

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004275567

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004768663

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 06037990

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020067007973

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006113366

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004768663

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067007973

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0414724

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10573353

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10573353

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2004275567

Country of ref document: AU

Date of ref document: 20040922

Kind code of ref document: B